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Abstract 
Acute or chronic inflammation in the prostate is implicated in pathogenesis of benign prostate hyperplasia 
(BPH) as well as development of prostatic intraepithelial neoplasia (PIN) and prostate cancer (PCa). Chronic 
prostatitis (inflammation in the prostate) is associated with high morbidity and negatively impacts life quality. 
Macrophages are critical regulators of inflammatory processes and are early immune cells responders. Among 
macrophage-associated genes, the stress-induced enzyme heme oxygenase-1 (HO-1), which degrades heme to 
carbon monoxide (CO), biliverdin and iron, has strong immunomodulatory effects in in vitro and in vivo disease 
models.  
In this study, we investigated the specific role of HO-1 in macrophages on modulation of prostate inflammation. 
We established a mouse model of bacterial prostatitis in wild type mice, and evaluated the role of HO-1 in 
pathogen-induced prostate inflammation by using mice with conditional deletion of HO-1 in myeloid cells 
(LysM-Cre:Hmox1fl/fl). Immunohistological analysis showed increased infiltration of CD45 positive leukocytes 
and mitosis in the prostate glands as represented by phospho-Histone-H3 (p-HH3) staining in mice after 
bacterial challenge. Inflammation was accelerated in mice lacking myeloid-derived HO-1 with increased 
number of CD45 positive cells in the prostate glands. Further, we confirmed activation of the mitogen-activated 
protein kinase (MAPK) signaling pathway as observed by increased phosphorylation of extracellular signal-
regulated kinase (Erk1/2) and induction of the inflammatory mediator interleukin-1β (IL-1β).  
Since exogenous CO mimics the majority, if not all, of the HO-1 effects, we asked whether CO plays a role in 
the model of prostatitis in mice. CO suppressed proliferation as shown by decreased p-HH3 staining and p-
Erk1/2 levels in the inflamed mice prostates. CO also suppressed bacteria-induced expression of lipid metabolic 
enzymes acyl-CoA synthetase-1 (ACSL1) and fatty acid synthase (FAS), which mediated macrophage 
activation in other inflammation models.  
In summary, these results suggest that HO-1 plays a role in modulating pathogen-induced prostate inflammation 
via suppression of leukocyte influx and that exogenous CO may be used to block inflammation trigged 
proliferation and prevent PIN lesion formation.  
 
Keywords: Prostate inflammation, myeloid derived HO-1, CO, lipid metabolism 
  
Lisa Vikström, Master’s Thesis 60 credits  2015-09-03 
Lund University, 2014-2015 
 
2 
 
 
Table of content 
Abstract................................................................................................................................................................1 
Table of content...................................................................................................................................................2 
Abbreviations.......................................................................................................................................................3 
1. Introduction........................................................................................................................................4-11 
1.1. Inflammation.................................................................................................................................4-5 
1.2. Prostatitis ………………………………………………………………………………………..5-6 
1.3. Prostate inflammation and the link to BPH and prostate cancer...................................................6-7 
1.4. Macrophage phenotype regulates cancer development and growth………..................................7-8 
1.5. Heme degradation pathway………...............................................................................................8-9 
1.6. Lipid metabolism in inflammation and prostate cancer…….........................................................10 
1.7. Aim……....................................................................................................................................10-11 
2. Material and methods……...............................................................................................................11-16 
2.1. Bacteria...........................................................................................................................................11 
2.2. Mice...........................................................................................................................................11-12 
2.3. Bone marrow isolation and bone marrow derived macrophages (BMDMs)..................................12 
2.4. Bacteria stimulation and CO treatment of BMDMs in vitro.....................................................12-13 
2.5. Cell culture and Soft Agar Colony Assay.......................................................................................13 
2.6. Western blot...............................................................................................................................13-14 
2.7. RNA isolation and real-time PCR...................................................................................................14 
2.8. Immunohistochemistry and immunostaining............................................................................14-16 
2.9. Statistical analyses..........................................................................................................................16 
3. Results..............................................................................................................................................16-23 
3.1. Establishment of in vivo model of pathogen-induced prostatitis...............................................16-17 
3.2. HO-1 is induced in prostatitis and influences infiltration of leukocytes to the prostate after 
intraurethral E.coli infection.............................................................................................................17-18 
3.3. CO suppresses proliferation in the prostate....................................................................................20 
3.4. Inflammation in the prostate induces lipid metabolic enzymes: Long chain acyl-CoA synthetase 
(ACSL1) and fatty acid synthase (FAS) – effect of CO and HO-1.......................................................21 
3.5. Anchorage independent growth of PC3 and PNT1A cells, respectively, is enhanced by E.coli 
induced macrophage derived factors, but can be suppressed in the former cell type by CO 
treatment...........................................................................................................................................22-23 
4. Discussion.........................................................................................................................................24-27 
5. Conclusion.............................................................................................................................................27 
6. Acknowledgement.................................................................................................................................27 
7. References........................................................................................................................................28-32 
 
 
  
Lisa Vikström, Master’s Thesis 60 credits  2015-09-03 
Lund University, 2014-2015 
 
3 
 
Abbreviations 
ACSL1        Long chain acyl-CoA synthetase 
BMDM        Bone marrow derived macrophage 
BPH        Benign prostate hyperplasia 
CCL2        C-C motif ligand 2  
CFU        Colony forming unit 
CO        Carbon monoxide 
COX-2        Cyclooxygenase-2 
CRCP        Castration resistant prostate cancer 
DAMP        Danger associated molecular pattern 
Erk        Extracellular signal-regulated kinase 
FAS        Fatty acid synthase 
FBS         Fetal bovine serum 
FGF-2        Fibroblast growth factor-2 
FOV        Field of view 
HH3        Histone H3 
HO-1        Hemeoxygenase-1 
HRP        Horse radish peroxidase 
IFN-γ         Interferon gamma 
IGF        Insulin-like growth factor 
IL (i.e. IL-1β)       Interleukin 
LB        Luria broth 
LPS        Lipopolysaccharides 
LUTS        Lower urinary tract symptoms 
MAPK        Mitogen-activated protein kinase 
MCP-1        Monocyte Chemoattractant Protein-1 
M-CSF        Monocyte-colony stimulating factor 
NIH        National institutes of health 
NFκB        Nuclear factor kappa B 
NLR Nucleotide binding domain leucine rich 
repeat containing receptors 
PAMP        Pathogen associated molecular pattern 
PBS        Phosphate buffered saline 
PI3K        Phosphoinositide 3-kinase 
PIA        Proliferative inflammatory atrophy 
PIN        Prostatic intraepithelial neoplasia 
PCa        Prostate cancer 
PCR        Polymerase chain reaction 
PRR        Pattern recognition receptors 
PSA        Prostate specific antigen 
PTEN        Phosphatase and tensin homolog 
RB        Retinoblastoma 
ROS        Reactive oxygen species 
STAT3 Signal transducer and activator of 
transcription 3 
TAMs        Tumor associated macrophages 
TBS         Tris buffered saline 
TGF-β         Transforming growth factor beta 
TNF        Tumor necrosis factor 
TLR        Toll-like receptor 
VEGF        Vascular endothelial growth factor 
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1. Introduction 
The majority of men will at some point during life experience prostate related problems. Benign prostate 
hyperplasia (BPH) and prostate cancer (PCa) are the most prevalent conditions of the urinary tract in males, 
despite progress in diagnosis and treatment in recent years (1). BPH affects 50 % of men in their 50’s-60’s and 
over 90 % in men over 80 years (2) and is caused by hyperproliferation of cells in the transition zone of the 
prostate gland (3). Enlargement of the prostate because of BPH may lead to obstruction of the urethra, pain, 
bladder dysfunction and urine retention (4, 5). PCa is one of the most common cancer types in the male 
population in Western countries (6, 7). In spite of improved screening methods and control in early stages, PCa 
still leads to a great number of cancer related deaths due to lack of effective treatment of advanced and metastatic 
disease (8). BPH and PCa are considered to be the result of several cooperating risk factors including heredity, 
age and hormones (9). In addition, a growing body of evidence based on human patient material samples as 
well as in vitro and in vivo studies have linked development and progression of proliferative disorders in the 
prostate to acute and chronic inflammation (10-13). 
1.1. Inflammation 
Inflammation is an essential component of the immune responses to pathogens or tissue injury and works to 
defend the host against harmful insults. It represents the initial response to any tissue damage and acts in a 
cause-independent manner to start the healing process of the affected area. The inflammatory processes are 
induced by the activation of tissue residing immune cells (leukocytes), primarily macrophages, in response to 
pathogens, stressed and damaged cells (14). Activation of macrophages occur via surface receptors (PRRs, 
pattern recognition receptors), such as toll-like receptors (TLRs) and nucleotide binding domain leucine rich 
repeat containing receptors (NLRs), recognizing signals from intruding microbes and stressed or damaged cells. 
Pathogen associated molecular patterns (PAMPs) including bacteria-derived lipopolysaccharides (LPS) or 
peptidoglycan bind TLRs, whereas nucleotides, such as extracellular ATP, mitochondrial DNA and other danger 
associated molecular patterns (DAMPs) related to cellular stress and necrosis, can activate multiple classes of 
receptors including NLRs (15). Upon activation, macrophages start to produce pro-inflammatory cytokines (i.e. 
TNF, IL-1β and IL-6) (14) and chemoattractants (i.e. monocyte chemoattracting protein-1, MCP-1). These 
molecules stimulate recruitment of bone-marrow derived myeloid cells (e.g. neutrophils and monocytes) to the 
site of inflammation. In response to PAMPs or DAMPs, recruited macrophages are polarized into a pro-
inflammatory, cytotoxic phenotype (M1 type). acting to eliminate bacteria or abnormal/tumor cells. By release 
of cytotoxic agents, including reactive oxygen species (ROS), as well as by activation of the adaptive immune 
system, the inflammatory cells work to clear tissues from pathogens and damaged cells (14). When the clearance 
of pathogens/cells is completed, macrophages phenotypically change grasping an anti-inflammatory profile (M2 
type). M2 polarized macrophages orchestrate tissue repair and regeneration by production of anti-inflammatory 
cytokines transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10) and stimulation of growth 
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factors, such as epithelial-, insulin-like- and vascular endothelial growth factor (EGF, IGF and VEGF) in order 
to accelerate healing processes and restore homeostasis in the injured tissue (16-18). Inflammation is absolutely 
necessary for host survival, but if not resolved it contributes to pathogenesis and development of various 
diseases. Chronic inflammation is a pathological condition that can be caused by autoimmune reactions or 
sustained infection. An unresolved inflammation is associated with presence of large numbers of immune cells, 
from which continuous release of ROS and pro-inflammatory mediators causes harm to the tissue by promoting 
cell death, inducing DNA damage and changes in the extracellular matrix (19). Examples of such syndromes 
are rheumatoid arthritis (20), diabetes mellitus (21, 22), atherosclerosis (23) and chronic inflammatory bowel 
disease (24). Hereditary factors have been identified as drivers in many immune mediated diseases, but only in 
combination with other risk factors they results in development of disease (25). Diabetes and cardiovascular 
disease are associated with dietary factors, smoking and the level of physical activity (26, 27). In addition, 
repeated contact with foreign substances or microbes in the colon, or infections in the urinary tract may trigger 
immune responses and activation of immune cells that are sustained over longer periods of time and influence 
function of these organs (28, 29). Chronic inflammation has also been strongly associated with development 
and progression of 20 % of all cancer diseases (i.e. gastric cancer, colon cancer and prostate cancer) (16). 
Immune cell derived toxic molecule- and ROS incited DNA-damage in combination with defect repair and 
increased stimulation of proliferation have been shown to induce oncogene activation, loss of function of tumor 
suppressor genes, and malignant transformation of epithelial cells in sites of chronic inflammation (19, 30). 
Further, immune cells and inflammatory factors, such as cytokines and growth factors, including EGF, IGF and 
VEGF, are involved in growth and spread of established tumors by promoting cell migration, angiogenesis and 
remodeling of the extra cellular matrix (16). 
1.2. Prostatitis 
The prostate is an exocrine gland and a part the male reproductive system, which produces fluid nourishing and 
allowing for transport of sperm during and after ejaculation. The prostate is located below the urinary bladder, 
surrounding the upper part of the urethra (31). In such a proximity to the urine, prostate is constantly at risk of 
being exposed to potential urine reflux and infectious agents (i.e. bladder infection) (32). Prostate inflammation, 
called prostatitis, is a common urogenital tract condition in men over 50 years of age, which is frequently found 
in prostate specimen from biopsies or autopsies (33, 34). Prostatitis can be initiated by a variety of stimuli and 
has been associated with sexually transmitted organisms, such as Chlamydia trachomatis, Trichomonas 
vaginalis and Neisseria gonorrhea, viruses (e.g. human papilloma and herpes simplex), as well as gram negative 
bacteria (i.e. uropathogenic Escherichia coli) and the opportunistic pathogen Propionibacterium acnes (9, 35-
40). P.acnes was able to establish chronic prostatitis in mice with persistent infiltrates of lymphocytes and 
macrophages 8 weeks after infection (41). When cocultured with prostate epithelial cells (RWPE1 cell line) 
P.acnes (isolated from human prostate tissue) activated inflammation related factors, such as nuclear factor 
kappa B (NFκB) and signal transducer and activator of transcription 3 (STAT3), and upregulated pro-
inflammatory genes including IL-6, IL-8 and cyclooxygenase-2 (COX-2) (42). E.coli is one of the most frequent 
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uropathogens to be detected in prostate tissue samples and is also associated with increased infiltration of 
immune cells and expression of inflammatory mediators (43, 44). Of note, both P.acnes and E.coli have been 
shown to increase the production and release of IL-1β from macrophages via activation of the Nalp3-Caspase1 
inflammasome (45, 46). In a rat model of sterile (non-bacterial) prostatitis, increased inflammasome activity 
was hypothesized to have significant impact on the pathology of chronic prostatic inflammation and related 
symptoms (47). Dietary factors, hormones and autoimmune responses contribute to the early steps of prostatitis. 
In addition, urine reflux and calcifications in the tubular tissue of the prostate increases risk of cytotoxicity from 
urine metabolites (e.g. uric acid crystals), physical trauma due to augmented pressure on the cells, and prostate 
infection, all contributing to trigger inflammatory responses (9). The National Institutes of Health (NIH) 
classifies prostatitis as one of four different categories: 1) Acute bacterial prostatitis, 2) Chronic bacterial 
prostatitis, 3) Non-bacterial chronic prostatitis and 4) Asymptomatic chronic prostatitis (48). An acute bacterial 
prostate infection is usually successfully treated with antibiotics for a period of 2-4 weeks (49). Chronic 
prostatitis on the other hand is a poorly understood, but common condition in men and is often associated with 
recurrent urinary tract infections, severe lower urinary tract symptoms (LUTS) (bladder voiding and filling 
problems), urogenital pain and sexual dysfunction over months or years, even in men as young as 20 years old 
(50). Limited knowledge on the pathology, and symptoms overlapping with other prostate conditions have so 
far been hurdles in search for effective treatment. Chronic inflammation has in addition been strongly associated 
with hyperplasia and cancer in the prostate (13, 51, 52). 
1.3. Prostate inflammation and the link to BPH and prostate cancer 
Inflammation as a driver of hyperplasia and tumor development and progression in the prostate has been 
suggested in a great number of studies. As in many types of cancer, cytotoxic and oxidizing agents released 
from inflammatory macrophages are thought to promote accumulation of mutations and increase in genomic 
instability with subsequent cellular transformation that can initiate tumor formation in the prostate. Presence of 
lymphocyte and macrophage infiltrates (53-55), as well as expression of inflammatory cytokines (e.g. IFN-γ, 
IL-17, IL-15 and IL-8) (53, 54, 56-58) and growth factors (FGF-2, VEGF and TGF-β) (59) in tissue samples 
from BPH patients have been positively correlated with higher prostate volume and LUTS severity. Patients 
with documented BPH treated with non-steroid anti-inflammatory drugs showed beneficial effect on LUTS (60) 
and antibiotics significantly decreased prostatitis related elevated serum PSA (prostate specific antigen) (61). 
The regenerative potential within the inflamed prostate is thought rely on a complex interplay between immune 
cells, stromal components and epithelium, involving hormonal regulation by the male sex-hormones 
testosterone and dihydrotestosterone (62). The steroid hormone signaling controls the differentiation program 
of prostate epithelial cells by paracrine signaling in normal prostate and is known to be deregulated in the 
majority of advanced prostate cancers (63).  
Moreover, patients biopsies with increased inflammation in the prostate, referred to as proliferative 
inflammatory atrophy (PIA) have been associated with pre-cancerous prostate intraepithelial neoplasia (PIN), 
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and potentially adenocarcinoma (64-66). Elkahwaji et al. showed that chronic bacterial infection of the prostate 
in a mouse model led to the development of PIN lesions within 3 months after induction of prostatitis by 
intraurethral injection of E.coli. After one week of infection the mice showed infiltration of leukocytes into the 
prostate stroma and after 26 weeks the prostate epithelium underwent transformation, shown by increased 
epithelial DNA-damage and proliferation, as well as by lower expression of the tumor suppressors PTEN and 
p27Kip1 (67). P.acnes isolated from human biopsies was also able to establish chronic prostatitis in a mouse 
model by transurethral inoculation, resulting in increased proliferation (represented by Ki67) and suppression 
of Nkx3 (prostate specific protein, often lost in hyperplasia and PCa) (41). The hypothesized association 
between bacteria induced prostatitis and tumor development was further supported by a study by Fassi Fheri 
and colleagues found P.acnes in over 80 % of 71 biopsies from cancerous prostates, while bacteria were absent 
in healthy control tissues. In addition, long-term infection caused transformation with enhanced proliferation 
and anchorage-independent growth of prostate epithelial cells (42). Intracellular P.acnes infection in prostatic 
macrophages have also been found in significantly higher numbers in prostate cancer tissue samples than in 
normal tissue (68). 
1.4. Macrophage phenotype regulates cancer development and growth 
Macrophages are excellent modulators of inflammatory responses and have crucial roles in destruction harmful 
pathogens and transformed cells, as well as in promoting healing processes and tissue regeneration. However, 
immune cells are active players in chronic inflammatory diseases and cancer. Tumor progression is shaped by 
residential and infiltrating innate immune cells. In general, tumors are characterized by a larger number of 
infiltrating myeloid cells and macrophages as compared to healthy tissues (69, 70). Tumor-associated 
macrophages (TAMs) are recruited to the tumor site by chemoattractants, especially CCL2, produced by cancer 
cells, and modulate angiogenesis, tumor growth and metastatic spread (71). TAMs are as well as normal 
macrophages classified into M1 or M2 subtype, induced by IFN-γ or IL-4/IL-13, respectively (72). M1 
macrophages possess cytotoxic activity and are capable of eliminating cancer cells and reducing tumor growth 
(73). In contrast, the immuno-suppressive M2 like macrophages, associated with pro-angiogenic capacity in 
response to local hypoxia (74), have been linked to poor prognosis and chemotherapy resistance in cancer 
patients (75, 76).  However, in early changes of the epithelium, called transformation, chronic pro-inflammatory 
responses are related to development of neoplasia (19). The macrophages present in chronically inflamed tissues 
share characteristics with M1 subtype, even though this polarization state generally is involved in anti-tumor 
immunity and infection defense. M1 macrophages have also been recognized to potently induce epithelial-
mesenchymal-transition, a characteristic of tumor invasion and migration, in pancreatic ductal carcinoma (77). 
However, the paradigm of macrophage polarization into M1 and M2 subtype is a radical simplification of the 
reality. Mixed or hybrid populations of M1/M2 like macrophages with simultaneous production of pro-
inflammatory (TNFα and IL-1β) and anti-inflammatory (IL-10) cytokines have been discovered in several 
studies, such as in early stages of PCa in transgenic mouse models (78) as well as in obesity related chronic 
inflammation in adipose tissue (79). Studies like these indicate a skewed inflammatory process with oxidative 
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stress and regenerative potential creating a reactive microenvironment with increased concentrations of growth 
factors and damaged cells, favoring transformation and tumor development. The regulation and switching of 
the macrophage polarization in tumor microenvironments is poorly understood and illuminates the complexity 
of the crosstalk between cancer and the immune system. Deeper understanding of the underlying mechanisms 
of tumor development and the role of chronic inflammation may contribute to the finding of new treatment 
regimens and targets in the combat against cancer. 
1.5. Heme degradation pathway 
Heme is an organic, iron containing protoporphyrine IX molecule that when bound to hemo-proteins is involved 
in various essential biological processes, such as gas transport, electron transfer and drug metabolism. Free 
heme on the other hand have serious cytotoxic and pro-inflammatory properties, due to its highly oxidative 
potential (80). Degradation of heme and recycling of iron is performed by the hemeoxygenase enzymes (HO-1 
and 2), which produce equimolar amounts of biliverdin, ferrous iron and carbon monoxide (CO) (81, 82). 
Biliverdin is immediately reduced by the biliverdin reductase (BVR) into the strong anti-oxidant bilirubin. HO-
2 is constitutively active in various tissues sustaining homeostatic levels of heme in the body, while HO-1 is 
induced by increased intracellular concentrations of free heme, oxidative stress and bacterial endotoxin (83). 
HO-1 have been shown to have strong cytoprotective effects in in various cell types. By degrading excess free 
heme HO-1 directly prevents generation of ROS, oxidative stress and tissue damage. In addition, HO-1 and its 
produced metabolites have been shown to play important roles in immuno-modulation. Transgenic mice with 
HO-1 deficiency have been characterized with higher degree of inflammation and sensitivity to heme toxicity, 
indicating an anti-inflammatory function of HO-1 in these animals (84). Biliverdin and bilirubin are strong anti-
oxidants countering free heme oxidative activity. The enzyme BVR has also been recognized as a transcription 
repressor of TLR4 and as an activator of Akt-IL-10 signaling, with strong influences on inflammation and cell 
death (85, 86).  
Further, the HO-1 byproduct CO has been described a potent immunomodulator in  various scenarios, such as 
sepsis, malaria (87, 88) and ischemia-reperfusion injury (8, 89) and have classically been associated with anti-
inflammatory properties (90-92). Exogenously administrated CO prior to insult has been beneficial in several 
models, such as in case of promoting tolerance of transplanted allografts (93, 94). Also, anti-inflammatory 
effects of CO have been described by Otterbein and colleagues on immune cell activation, by blocking TNF 
release from endotoxin activated macrophages (91). Results from these studies and others suggest that CO has 
a therapeutic potential and is currently evaluated in several clinical trials in cases of for instance organ 
transplantation and pulmonary hypertension www.clinicaltrials.gov (2015-04-29).  
Intriguingly, HO-1 and CO has recently also been implicated in immuno-stimulatory processes, for instance in 
driving to pathologic inflammation and insulin-resistance in in humans and mice with obesity and diabetes (87). 
In addition, CO treatment after infection acts to increase bacterial clearance (95) and even amplify pro-
inflammatory responses in macrophages after bacterial challenge, by up-regulation of IL-1β activation and 
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release (96). In the later scenario CO protects from lethal sepsis through enhanced bacteria killing by 
macrophages, via a unique mechanism acting directly on bacteria via activation of the Nalp3-Caspase1 
inflammasome. In the proposed mechanism HO-1 is induced by bacterial PAMP stimulation of TLR4 and 
produces CO. By diffusion, the CO reaches live bacteria in the intracellular space and provoke the pathogens to 
release extra cellular ATP, acting as a DAMP and co-stimulatory signal, binding to the macrophage P2X7 
receptor (96). Nucleic acid stimulation of P2 receptors activates the internal NLR3 (Nalp3), which in association 
with Caspase 1 induces processing of IL-1β (97-100). We hypothesized that ATP released from necrotic cancer 
cells in the tumor microenvironment work in the same way to activate TAM. IL-1β has been shown to block 
proliferation and important signaling pathways of prostate cancer cells (101).  
HO-1 has also been associated with cancer (89). Conflicting results from multiple studies indicate that HO-1 
effects differ depending of cancer type and stage of progression (102). An elevated epithelial HO-1 expression 
has been detected in renal cancer, colon cancer and pancreatic cancer (103-106). On the other hand, HO-1 
expression was proven repressed in macrophages present in non-small lung carcinoma (107). In prostate cancer, 
HO-1 has been suggested to interfere with several different processes and pathways, linked to both tumor 
progression as well as anti-tumor activity. HO-1 overexpressing PC3 cell xenografts in immunocompromised 
mice showed significant reduction in tumor growth compared to control mice implanted with wild type PC3 
cells. In vitro, HO-1 induction resulted in reduced proliferation and migration in PC3 cells (108) as well as 
blockage of NFκB signaling and angiogenic factors, such as VEGF-receptor (109). CO treatment mimics HO-
1 effects and suppressed the growth of LNCaP and PC3 cells by inhibiting phosphorylation of the cell cycle 
guardian RB, (110) and to cause growth arrest in moderately differentiated prostate tumors in mice by inducing 
mitotic catastrophe (111). During normal conditions HO-1 operates in the cytoplasm, but nuclear localization 
of a truncated and enzymatically restricted form of the protein (112) has been associated with prostate cancer 
(105). Nuclear HO-1 has been recognized to modulate Androgen Receptor activity through interference with 
STAT3, a transcriptional activator that is often deregulated in cancer (113). In addition, high epithelial 
expression of HO-1 has been positively correlated with castration resistant prostate cancer (CRPC) and tumor 
suppressor PTEN deletion (114). Inhibition of HO-1 in CRPC reduced invasion and metastasis (106). Since 
inflammation has been assigned a “hallmark of cancer” (115) and estimated to be a direct or indirect cause of 
tumor development in 20 % of all cancers, a huge research is currently conducted trying to identify new targets 
for treatment, as well as diagnostic and prognostic factors. The polarization status of macrophages has been 
proven to be determinants of function in chronic inflammatory settings and in cancer development and 
progression. Previous data from our group showed strong induction of HO-1 in macrophages after infection 
with E.coli or Escherichia faecialis, strains often involved in urinary tract infections and were associated with 
M1 like phenotype (96). At present, the function of macrophage derived HO-1 in bacteria induced prostate 
inflammation has not been investigated.  
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1.6. Lipid metabolism in inflammation and prostate cancer 
Lipids are used for many essential processes by the cells, including storage of energy, generation of cellular 
membranes, and synthesis of lipid derived hormones. In normal cells, fatty acids are generally originating from 
food, while de novo synthesis of fats is almost absent, with exception of liver, breast and adipose tissue (116). 
Cancer cells were early described to have a deregulated metabolism, characterized by increased glycolysis, in 
spite of adequate oxygen levels (117). Highly proliferative tumor cells are also dependent on increased lipid 
production to cover the need of energy and to be able to generate new cells. Several lipid metabolic enzymes 
have been shown to be upregulated in various types of cancer, including prostate cancer (118). Fatty acid 
synthase (FAS) is active in the de novo synthesis of fatty acids and has been associated with tumor progression, 
malignant transformation and poor prognosis (116). Overexpression of FAS in prostate cancer cells lead to 
augmented proliferation and inhibition of cell death in vitro (119). Mechanistically, FAS has been associated 
with activation of PI3K-Akt signaling (implicated in many cases of PCa) (120) and androgen signaling in the 
prostate (121). Long chain acyl-CoA synthetase 1 (ACSL1) is one of 5 iso-forms of an enzyme that works to 
activate fatty acids for further metabolic processes by coupling them to Coenzyme A, generating acyl-CoA 
molecules. Except for being upregulated in tumors (116), ACSL1 is activated by bacterial infection via a TLR4 
dependent mechanism and mediates the phospholipid turn over in LPS stimulated macrophages (122). In 
addition, conditional deletion of ACSL1 in macrophages prevented acceleration of atherosclerosis in diabetic 
mice. This indicates a role of ACSL1 in promoting the polarization of macrophages into pro-inflammatory 
phenotype, mediating chronic inflammation in this disease model (123). Since lipid metabolic enzymes, such 
as FAS and ASCL1 have been shown to regulate immunological reactions and/or malignant transformation and 
heme degradation pathway is linked to metabolic stress, we hypothesized that ASCL1/FAS are regulated in our 
model of prostatitis by the presence of HO-1/CO. 
1.7. Aim 
In this study, we investigated the role of HO-1 in macrophages and its effects on bacteria induced inflammation 
in the prostate. To do this, we established a mouse model of bacterial prostatitis, induced by intraurethral 
inoculation of E.coli (43, 65, 67), and examined how selective deletion of HO-1 in myeloid cells and application 
of CO influenced the development of inflammation. We focused on the following questions: 
1. How does selective deletion of HO-1 in macrophages influence development of inflammation that leads to 
tumorigenesis in the prostate?  
2. Will application of CO regulate inflammation in the prostate to prevent development of cancer? 
In addition, we used in vitro based methods to look at the influence of macrophage derived factors and CO on 
malignant phenotype in prostate derived cell lines PNT1A (transformed epithelium) and PC3 (adenocarcinoma). 
As a sub-aim, we investigated whether lipid metabolic enzyme expression in inflamed prostate tissue is 
regulated by CO treatment.  
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The goal of the study is to obtain valuable knowledge about the inflammatory process and its regulation in 
bacterial prostatitis, focusing on the heme degradation pathway enzyme HO-1. Targeting inflammation and 
inflammation regulated factors could possibly represent an alternative in anti-cancer therapy. Since CO have 
shown suppressive effects on prostate tumor cells in vitro and in xenograft experiments, there is a hope for 
future clinical applications of this gaseous molecule as therapy in prostate cancer/prostatitis patients.  
 
2. Material and Methods 
2.1. Bacteria 
Escherichia coli MG1655, originally acquired from the Keio library, was provided by Bernard Strauss 
(Massachusetts Institute of Technology [MIT], Cambridge, Massachusetts, USA). This strain of bacteria was 
used in bacterial infection experimentations in vitro and in vivo. Bacteria were inoculated in Luria Broth (LB) 
medium (Invitrogen™, Life Technologies, Carlsbad, CA, USA) from a frozen aliquot obtained from a single 
colony, and incubated overnight (o/n) at 37 °C on orbital shaker. Fresh LB was inoculated with 1 ml aliquot of 
the o/n culture and sub-cultured for 1.5h at 37 °C. Cells were pelleted at 3220 x g (5 min) and resuspended in 
sterile Phosphate Buffered Saline (DPBS -Cl -Mg) pH 7.4 (Gibco® Life Technologies). Optical density of 
bacteria suspension was measured at 600 nm (OD600) and adjusted with PBS to 0.45. Serial dilutions of stock 
suspension (1:1000-1:109) were plated in duplicates on LB-agar and incubated at 37 °C o/n. Colony counts were 
averaged and used to estimate the concentration of bacteria (CFU/ml) in the prepared stock with OD600=0.45. 
Appropriate volumes of the bacteria dilutions were used to prepare injections for infection in vivo or for in vitro 
treatments.  
Optimizing of an in vivo dose of bacteria: Intraurethral injection of a single dose of bacteria at 2x105, 2x107 
and 2x108 CFU/animal (n=2/group) was performed. Mice injected with 50 µl PBS and naïve mice, respectively, 
were used as negative controls. Inflammation as tested by increased number of CD45+ cells in tissue was 
evaluated in the prostates harvested 2 weeks after infection. A higher degree of inflammation was observed in 
mice injected with the highest dose of bacteria, 2x108 CFU/ml, which therefore was used in all following 
infections in vivo. Further since the PBS-injected mice also showed signs of inflammation in the prostate they 
were hereafter used as a model of sterile inflammation, while mice catheterized but not injected with PBS or 
bacteria (‘tubing’ group) were used as negative controls in addition to naïve animals.  
2.2. Mice 
C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME, USA) 7-10 weeks of age weighing 20-25 g were used 
(after at least three days of acclimatization) to establish models of pathogen induced and sterile prostatitis 
through intraurethral (i.u.) instillation of Escherichia coli MG1655 (2x108 CFU/ animal) and PBS, respectively 
(n=3-6/group). Injections were done using a 30G syringe connected to lubricated polyvinyl tubing (outer 
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diameter 1.2 mm) inserted into the urinary bladder via the urethra. The procedures were performed under 3 % 
isoflurane induced anesthesia. After procedure the mice were monitored for changes in behavior associated with 
pain or distress and body weight records were kept. The animals were kept at all times in ventilated cages (up 
to 5 individuals per cage) in a 12 hours light-dark cycle provided water and food ad libitum. The procedures 
were approved by Institutional Animal Care and Use Committees at Beth Israel Deaconess Medical Center, 
Harvard Medical School, MA, USA. Prostates and blood samples were harvested from the different mice groups 
2h, 6h, 24h and 3 weeks after injection and analyzed by immunohistochemistry (CD45 and pHH3), real time 
PCR (rtPCR) with primers against IL-1β and IL-10 and western blot. The same time points as indicated above 
were chosen for investigation of the role of carbon monoxide (CO) in this model. Animals injected with E.coli 
or PBS as well as negative controls inhaled CO (250 ppm) for 1h, starting 1h after injection. The role of myeloid 
derived HO-1 in bacteria-induced or sterile prostatitis was investigated by using conditional knockout mice 
deficient in HO-1 in myeloid cells. These animals were generated by crossing mice having the Hmox1 gene 
flanked with LoxP sites (Hmoxfl/fl), provided by the RIKEN BRC through the National Bio-Resource Project, 
Japan, with transgenic mice expressing Cre recombinase under control of the myeloid specific LysM-promoter 
(LysM-Cre) (Jackson Laboratories). LysM-Cre:Hmox1fl/fl homozygotes were verified by PCR based genotyping 
(124).  
2.3. Bone marrow isolation and bone marrow derived macrophages (BMDMs) 
Intact femurs were isolated from WT mice euthanized by overdose of xylazine and cleaned from soft tissues. 
Bones were crushed in a mortar and cells were washed in RPMI (Life Technologies) containing 1% Anti-
microbial & anti-fungal solution (A/A) (Life Technologies) (wash medium). Cells were passed through 40 µm 
strainers and spun at 453 x g for 5 min and resuspended in fresh wash medium. Red blood cells were lysed using 
Buffer EL (Qiagen, Hilden, Germany) for 5 min. The reaction was blocked by RPMI containing 15 % Fetal 
Bovine Serum (FBS) (Atlanta Biologicals, Norcross, GA, USA). Cells were washed two times with the wash 
medium before resuspended and diluted in macrophage differentiation media (RPMI 15 % FBS 1 % A/A 
containing M-CSF, 20 ng/ml (Peprotech, Rocky Hill, NJ, USA). Cells were plated in cell culture treated 100-
mm dishes (1 plate per femur isolated) and differentiated at 37 °C, 5 % CO2, 95 % humidity for 5 days. Media 
was changed on day 3 after isolation and the macrophages were used for experiments on day 5. 
2.4. Bacteria stimulation and CO treatment of BMDMs in vitro 
BMDMs differentiated with M-CSF (20 ng/ml) for 5 days were scraped off the culture dishes and suspended in 
fresh RPMI, 10 % FBS, 1 % Penicillin-Streptomycin medium (Life-Technologies). The cells were counted and 
replated in 100-mm dishes (3x106 cells per plate). Bacteria (E.coli MG1655) were prepared as described above 
(see section ‘Bacteria’). Macrophages were washed twice in PBS to remove residual antibiotics and were then 
stimulated with bacteria (10 MOI) for 1h in antibiotic free culture media. Sterile PBS pH 7.4 was added to 
control plates. Macrophages from stimulated and control groups were treated with CO (250 ppm) or air for 1h. 
Bacteria were removed after 2 hours stimulation and medium containing antibiotics (1 ml medium per 170 000 
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cells) was added to the plates. Supernatants from the BMDMs were harvested 24h after stimulation, filtered and 
stored at -20 °C until use.  
2.5. Cell culture and soft agar colony assay 
One preliminary colony assay was performed in triplicates to investigate anchorage independent growth in 
prostate epithelial PNT1A (transformed cell line) and PC3 (prostate adenocarcinoma cell line) cells using a 
three dimensional culture system in soft agar. A modified version of a protocol (Wallert and Provost Lab, 
Minnesota State University Moorhead, MN, USA 
http://web.mnstate.edu/provost/Soft%20Agar%20Assay%20Protocol%202012.pdf (2014-11-04) was followed 
using 6 well plates with 5000 cells per well. A base layer with 0.5 % sterile agar RPMI 10 % FBS 1% 
penicillin/streptomycin (Life Technologies) was casted into 6 well plates, 1 ml per well and solidified. Cells 
grown to 60-80 % confluence in RPMI 10 % FBS were deattached by trypsinization and diluted to the final 
concentration of 1x104 cells/ml in RPMI 20 % FBS 2 % P/S. Each suspension was mixed 1:1 with sterile soft 
agar 0.7 % (37-39 °C) (final concentration 0.35 % agar 10 % FBS) and applied to each well on top of the base 
layer and let incubate o/n).  
The cells in the soft agar were treated for 2-3 weeks with supernatants from differentiated BMDMs treated with 
bacteria at 10 MOI and CO (see section ‘Bacteria stimulation and CO treatment of BMDMs’). Medium was 
changed every third day (0.5 ml per well per time). RPMI 10 % FBS was used as negative control.  
2.6. Western blot 
Prostate tissue was sonicated in lysis buffer (50 mM Tris-Cl pH 7.0, 150 mM NaCl,  0.5 % NP-40, 2 mM EDTA, 
25 mM NaF, 0.1% SDS, 1 tablet/10 ml buffer Complete Mini Protease Inhibitor Cocktail) (Roche, Indianapolis, 
IN, USA). The lysates were centrifuged (Microfuge 18 Centrifuge, Beckman Coulter, Bromma, Sweden) for 20 
min at 18 000 x g and supernatants were transferred to clean Eppendorf tubes. The centrifugation was repeated 
once more and clear supernatants were transferred to new Eppendorf tubes. The protein concentrations in the 
samples were measured using Pierce BCA Protein Assay (Thermo Scientific, Waltham, MA, USA) according 
to manufacturer’s instructions. The samples were adjusted with dH2O to equal concentration. Samples were 
prepared for electrophoresis by adding 4x sample buffer (Life Technologies) containing 10 % β-
Mercaptoethanol and boiled for 5 min. Samples were loaded (20-25 µg/well) in NuPAGE® Novex® 4-12% 
Bis-Tris Protein Gels (Life Technologies) using Precision Plus Protein™ Kaleidoscope™ (Bio Rad, Hercules, 
CA, USA) as size marker. Electrophoresis was performed in MES SDS running buffer (Life Technologies) at 
90-120V. Separated proteins were transferred to PVDF membranes (Amersham, Piscataway, NJ, USA) in 
transfer buffer (33 mM Tris, 0.19 M Glycine, 20 % Methanol) at 80V for 1.5h. Membranes were blocked in 5 
% fat-free milk in TBS (50 mM Tris-HCl, pH 7.0, 150 mM NaCl) for 1h followed by incubation with primary 
antibodies: HO-1 1:1000 (ab13248, Abcam, Cambridge, MA, USA), ACSL1 1:1000 (D2H5) (#9189 Cell 
Signaling, Beverly, MA, USA), Fatty Acid Synthase 1:1000 (C20G5) #3180 Cell Signaling), IL-1β 1:500 
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(ab1413, Millipore (Billerica, MA, USA), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 1:1000 (#9101, 
Cell Signaling, Beverly, MA, USA) Cleaved Caspase-1 p10 (M-20) 1:1000 (sc-514, Santa Cruz Biotech, Dallas, 
TX, USA), TLR4 1:1000 (ab13556, Abcam, Cambridge, MA, USA), β-Actin (A5316 Sigma Aldrich, St. Louis, 
MO, USA) o/n at +4° C. After overnight incubation, membranes were washed in 1x Tris-Buffered saline (TBS) 
for 2*10 min and then incubated with Horse Radish Peroxidase (HRP)-conjugated secondary antibodies (Anti-
mouse IgG, HRP-linked Antibody (#7076, Cell Signaling) or Anti-rabbit IgG, HRP-linked Antibody (#7074, 
Cell Signaling) at 1:5000 dilution for 1h at RT on orbital shaker, followed by  washing twice for 15 min in TBS. 
Proteins were detected on radiofilm after signal development with SuperSignal™ West Pico Chemiluminescent 
Substrate and SuperSignal™ West Femto Chemiluminescent Substrate (Thermo Scientific). The results were 
correlated with a loading control represented by the house-keeping protein β-Actin. Before re-probing with 
different antibodies, membranes were stripped in ReBlot Plus Strong Antibody Stripping Solution (Millipore, 
Billerica, MA, USA) for 10 min. Membranes were washed in TBS for 20 min and stored until re-probed.  
2.7. RNA isolation and Real-time PCR 
Total RNA was isolated from prostate tissues according the manufacturer’s instructions using RNeasy Mini 
RNA Isolation Kit (Qiagen, Hilden, Germany). cDNA was synthesized with iScript™ cDNA synthesis kit 
(BioRad) using 1 µg isolated RNA following the manufacturer’s protocol: 25 °C, 10 min; 37 °C, 2h; 85 °C 5 
min. mRNA expressions were measured by real-time PCR using SYBR-Green PCR Master Mix (Applied 
Biosystems, Life Technologies) and the following primers: IL-1β, forward: 5′-TGGGCCTCAAAGGAAAGA-
3′, reverse: 5′-GGTGCTGATGTACCAGTT-3′; IL-10, forward: 5′-CCAAGCCTTATCGGAAATGA-3′, 
reverse: 5′-TTTTCACAGGGGAGAAATCG-3′; β-actin, forward: 5′-TAGACTTCGAGCAGGAGATGGC-3′, 
reverse: 5′-CCACAGGATTCCATACCCAAGA-3′. The following program was applied: 95 °C, 10 min; 94 °C, 
30 sec; 58 °C, 55 sec; 72 °C, 1 min; 95 °C, 1 min; 55 °C, 30 sec; 95 °C, 30 sec (step 2-4 times 40 cycles). 
Standard software of Stratagen MxPro 3005P (Agilent Technologies, Santa Clara, CA, USA) was used to 
measure relative changes in mRNA levels.  
2.8. Immunohistochemistry and immunostaining 
Immunohistochemical stainings were performed for detection of markers of interest in the prostate tissue. 
Immunofluorescence and enzyme activity (Avidin-Biotin Complex) were used as detection systems. Sections 
were evaluated using light microscopy (Nikon, Tokyo Japan) or fluorescence microscopy (Zeiss Apotome 
Axiovert Fluorescence Microscope, Oberkochen, Germany) and pictures were taken at 10x and 40x 
magnification.  
Tissue fixation and preparation of sections: Prostate tissues were fixed in Zinc fixative (0.1M Tris-HCl, 0.5g/L 
Calcium Acetate, 5g/L Zinc Chloride, 5g/L Zinc Acetatedihydrate) for 48h, dehydrated in a series of alcohols 
with increasing percentages and treated with xylene, and then embedded in paraffin. The paraffin blocks were 
cut in 5 µm sections using microtome and mounted on microscope glass slides (Thermo Scientific, Waltham, 
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MA, USA). Deparaffinated and rehydrated sections were washed in dH2O three times for 2.5 min and placed in 
PBS pH 7.4 for 5 min. 
Immunostaining: Fixation of sections to slide and antigen retrieval were performed following the optimized 
protocol for each antibody as specified below (see CD45, p-HH3 and HO-1, respectively). After antigen 
retrieval sections were washed twice for 5 min in PBS and then incubated with 7% Horse Serum diluted in PBS 
for 30 min to block unspecific binding. Primary antibodies were applied on each section for overnight incubation 
at +4 °C. The following day slides were washed 3 times in PBS followed by 10 min blocking in 0.5 % hydrogen 
peroxide solution. After an additional wash in PBS, biotinylated secondary antibodies (Vector Laboratories, 
Burlingame, CA, USA) were diluted 1:300 in PBS and applied on each section and incubated at room 
temperature (RT) for 1h. Slides were washed twice for 5 min in 1x PBS. Avidin-Biotin peroxidase complexes 
were prepared from ABC-kit (VECTASTAIN®, Vector Labs) (2 drops of A, 2 drops of B in 10 ml PBS) and 
was let to stabilize at RT for 30 min and then applied on the slides and incubated at room temperature for 30 
min. The slides were washed twice for 5 min in 1xPBS before addition of 3, 3’-diaminobenzidine (ImmPACT™ 
DAB Peroxidase (HRP) Substrate, Vector Labs) to develop the staining for 1-2 min. The color reaction was 
blocked in dH2O for 5 min twice. Nuclei were counter-stained with hematoxyline and the sections were 
dehydrated in alcohol and xylene, covered in mounting medium and cover slips. The slides were evaluated 
microscopically (Nikon) and pictures were taken at 10x, and 40x magnification.  
Marker specific procedures for immunostaining: 
CD45: Deparaffinated, rehydrated and washed sections were cooled down in refrigerated PBS (4 °C) for 3 min. 
Antigen retrieval and fixation of tissue was performed putting the sections in cold acetone with 7 % formalin 
for 2.5 min. The slides were washed in cold PBS for 4-5 min and then transferred to 1x PBS at RT. Primary 
antibody: Rat Anti-mouse CD45 antibody (#553076 BD Pharmingen, San Diego, CA) 1:50 dilution in PBS. 
Secondary antibody: Biotinylated Rabbit Anti-Rat IgG (BA-4000, Vector Laboratories, Burlingame, CA, USA), 
1:300 dilution in PBS. 
pHH3: Deparaffinated, rehydrated and washed sections were fixed in 2% paraformaldehyde for 3 min and 
washed twice for 5 min in PBS. Sections were acidified in 0.1 M sodium citrate pH 6.0 for 5 min at RT and 
then transferred to warm solution of 0.1 M sodium citrate pH 6.0 (+93 °C) for 25 min. The container with hot 
citrate buffer and the slides were put in ice-water bath for 20 min to cool down. After antigen retrieval the slides 
were placed into RT PBS. Primary antibody: Rabbit anti-pHH3 (Ser10) #9701 (Cell Signaling, Beverly, MA, 
USA) 1:100. Secondary antibody: Biotinylated Goat Anti-Rabbit IgG (BA-1000, Vector Laboratories, 
Burlingame, CA, USA) 
HO-1: Fixation and antigen retrieval were performed as above for pHH3 with exception of warm sodium citrate 
being applied for 15 min. Primary antibody: Rabbit anti-HO-1 (ab13248, Abcam, Cambridge, MA, USA) 1:100. 
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Secondary antibody: Biotinylated Goat Anti-Rabbit IgG (BA-1000, Vector Laboratories, Burlingame, CA, 
USA) 
Immunofluorescence staining: Sections were fixed with 2% paraformaldehyde for 10 min following washing 
with PBS 3 times and permeabilization with 0.05 % Triton X-100 in PBS for 5 min and then washed twice for 
5 min in 1xPBS. 7 % Horse Serum diluted in PBS was used for blocking for 30 min. Primary antibodies applied 
on each section: ACSL1 (D2H5) Rabbit mAb (#9189 Cell Signaling, Beverly, MA, USA) 1:300 and CD45: Rat 
Anti-mouse CD45 antibody (#553076 BD Pharmingen, San Diego, CA) 1:50. Sections were incubated with 
primary antibodies overnight at +4 °C. The following day the slides were placed in PBS twice for 5 min and 
incubated at RT in darkness for 1h with secondary antibodies diluted 1:300 (Anti-Rat Alexa Fluor® 488, anti-
Rabbit Alexa Fluor® 594, Invitrogen/Life Technologies, Molecular Probes. After careful washing 2x5 min in 
PBS the nuclei were stained with Hoechst-33258 (Molecular Probes, Invitrogen) in dilution 1:10000. Slides 
were left for 5 min in PBS and then 5 min in MQ-H2O before they were left to air-dry in darkness. The slides 
were covered with Gelvatol, (Sigma) and glass coverslips. Zeiss Apotome Axiovert Fluorescence Microscope 
was used to evaluate the fluorescence staining.  
2.9. Statistical analyses 
All values are expressed as the average ± SD. All experiments were performed in duplicates or triplicates. Mice 
number: n=3-6/group. Samples were analyzed using 1-way ANOVA followed by Tukey’s multiple comparison 
test or Student’s t test (2 tailed). A result was considered significant if the p value was lower than 0.05. Analyses 
were performed using SPPS13.0 and/or Microsoft Office Excel 2007. 
 
3. Results 
3.1. Establishment of in vivo model of pathogen-induced prostatitis 
To investigate the role of myeloid-derived HO-1 and CO in pathogen-induced inflammation in the prostate in 
vivo, we established a mouse model of prostatitis by injecting live E.coli into the urinary bladder via a urethral 
catheter as previously described (65). We have first optimized a dose of bacteria and found that a dose of 2x108 
CFU E.coli suspended in 50 µl sterile PBS was sufficient to induce prostate inflammation. Experimental mice 
were injected intraurethrally (i.u.) with E.coli while control groups consisted of mice injected with the same 
volume of PBS or non-treated mice (naïve animals) (Figure 1A). Prostates from each group were harvested 
after 2h, 6h, 24h and 3 weeks after single dose of bacteria and were analyzed by immunoblotting, real time PCR 
and/or immunohistochemistry. There were no significant differences in the body weights between PBS versus 
E.coli groups 20 days after infection (Figure 1B).  
Immunohistological staining revealed increased infiltration of CD45+ leukocytes into the prostate tissue 
(Figure 1C-D), primarily to the stroma, as early as after 6h in both PBS or E.coli treated groups in comparison 
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to naïve controls. The infiltration of CD45+ cells was further increased in prostates from E.coli injected mice at 
the 24h time point and was significantly higher than PBS group, with a sustained effect on leukocyte infiltration 
up to 3 weeks after a single injection of bacteria.  
Further, we performed analyses of proliferation by immunostaining with antibody against a mitosis marker, 
phospho-Histone H3. Expression of P-HH3 showed was strongly induced after E.coli injection (Figure 1E-F). 
The number of P-HH3+ cells per FOV was elevated between 6h to 3 weeks in bacteria injected mice as compare 
to naïve animals. PBS injected mice also showed a significant increase in p-HH3 staining only after 24h as 
compare to normal tissue, but no difference was detected in earlier or later time points.  
Real time PCR performed on the prostate tissues from mice injected with bacteria (Figure 1E) showed a marked 
increase in pro-inflammatory cytokine pro-IL-1β mRNA. In contrast, IL-10 expression was suppressed by E.coli 
as well as PBS groups as compare to normal prostate from naïve mice.  
To evaluate signaling pathways that are implicated in the inflammatory processes in the prostate, we tested for 
MAPK and cytokine expression. We observed an induction of phospho-Erk1/2 and cMyc at 6h and 24h after 
injections of PBS or E.coli (Figure 1H), indicating activation of the MAPK-Erk1/2 signaling pathway, which 
is involved in proliferation and tissue regeneration in prostates of these mice. However, the result from the 3 
weeks’ time-point was inconsistent and not taken in into consideration, for example the naïve animal showed 
strong in induction of p-Erk1/2, indicating faulty biopsy harvesting. The established model was used to 
investigate the role myeloid derived of HO-1 in the settings of prostate inflammation. 
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Figure 1: Model of pathogen-induced prostatitis by transurethral instillation of E.coli in male wild type mice. (A). Illustration of the model 
established and used throughout the study. In the first step male WT mice (C57BL/6) were inoculated intraurethrally (i.u.) with E.coli M1655 (2x108 
CFU/animal) or injected with PBS i.u. Controls used were catheterized but not injected (tubing) or naïve (untreated) mice. After procedure mice were 
kept at standard conditions until sacrifice; 2h, 6h, 24h and 3 weeks after injection, respectively. Prostates were harvested and analyzed for inflammation 
and proliferation by Immunohistochemistry (IHC) immunoblotting and/or real-time (rt) PCR. In later experiments Mice were treated with carbon 
monoxide (CO), 250 ppm for 1h, starting 1h after injection, and were compared to mice kept in air. After establishment the model was also applied in 
conditional HO-1 knockout mice (LysM-Cre:Hmox1fl/fl) (All data shown in this figure represent wild type mice kept in standard conditions in air after 
procedure until time of euthanazation). (B). Left: Body weight records (grams) of mice from day 0 through day 20 after injection of PBS or E.coli (2x108 
CFU/animal), each curve representing one individual. Right: Change in body weight (grams) in mice inoculated i.u. with E.coli versus PBS injected 
animals from day 0 to day 20 after procedure. (C-D) Quantification and representative pictures of CD45+ cells (leukocytes) in prostate 6h, 24h and 3 
weeks after i.u. injection of PBS or E.coli (2x108 CFU/animal). (C). Number of CD45+ cells per field of view (FOV) in prostates from mice injected i.u. 
with PBS or E.coli (2x108 CFU/animal) versus Naïve controls at time points 6h, 24h and 3 weeks, respectively (n=2-3 individuals/group). Data shown 
as average ± SD. * P<0.05, ** P<0.01 *** P<0.001. (D). Representative pictures of CD45+ cells in prostate presented in C, arrows indicate stained 
cells. (E-F) Quantification and representative pictures of phospho-Histone H3+ (pHH3+) cells in prostate after 6h, 24h and 3 weeks in mice treated as 
in C. (E). Number of p-HH3+ cells per FOV in prostate from mice as described in C. Data shown as average ± SD. * P<0.05, ** P<0.01 *** P<0.001 
(F). Representative pictures of p-HH3+ cells in prostates from mice quantified in E, stained cells indicated by arrows. (G). Expression of cytokines IL-
1β (left) and IL-10 (right) presented as mRNA fold change in PBS or E.coli injected mice (2x108 CFU/animal) versus naïve controls (value normalized 
to 1) 2h after injection (n=3-4 animals/group). Data shown as average ± SD *P<0.05. (H). Immunoblot of phospho-Erk 1/2 and cMyc in prostate lysates 
from mice 6h, 24h and 3 weeks after i.u. injection of PBS or E.coli (2x108 CFU/animal). N=Naïve, β-Actin=loading control. 
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3.2. HO-1 is induced in prostatitis and influences the infiltration of leukocytes to the prostate 
after intraurethral E.coli infection 
We found that HO-1 was induced in mice prostates early on (2h) after i.u. injection of PBS or E.coli in 
comparison to naïve individuals (Figure 2A). Cells positive for HO-1 were localized by IHC primarily to the 
stroma after 3 weeks (Figure 2B). Since our hypothesis suggest that HO-1 is present in immune cells in the 
prostate, we further investigated the role of myeloid-derived HO-1. We used conditional knockout mice lacking 
HO-1 specifically in innate immune cells (LysM-Cre:Hmox1fl/fl) and compared the number of CD45+ and p-
HH3+ cells per FOV (Figure 2C-F) in these animals with wild type mice after challenge with bacteria or PBS 
i.u. as above. Quantification of IHC staining from mice 3 weeks after injection showed that the infiltration of 
CD45+ cells was augmented in LysM-Cre: Hmox1fl/fl mice as compare to Hmox1fl/fl mice in both PBS and E.coli 
exposed group (Figure 2C-D). In contrast, the rate of mitosis, represented by p-HH3+ cells, was independent 
on the HO-1 levels in the myeloid cells (Figure 2E-F).  
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Figure 2: Role of myeloid-derived HO-1 in prostate inflammation. (A-B) Immunoblotting IHC staining of HO-1 in inflamed prostate 
from wild type mice, 2h and 3 weeks after intraurethral (i.u.) injection of PBS or bacteria, respectively. (A). Relative quantity of HO-1 
measured by immunoblotting of prostate lysates from wild type mice sacrificed 2h after i.u. instillation of E.coli (2x108 CFU) or injection 
of PBS, compared to naïve controls. β-Actin=Loading control (B). Immunohistochemical staining of HO-1 in prostate tissue from naïve 
mouse versus animals harvested 3 weeks after induction of prostatitis via i.u. injection of PBS and E.coli, respectively, performed as in 
A. Examples of stained cells are indicated by arrows. (C-D) Quantification and representative pictures of CD45+ cells in prostates from 
conditional myeloid-specific HO-1 knock-out mice (LysM-Cre:Hmoxfl/fl) compared to Hmox1fl/fl (WT) mice, 3 weeks after PBS or E.coli 
injection i.u. (2x108 CFU/animal). (C). Number of CD45+ cells per FOV in prostate, 3 weeks after i.u. injection of PBS or E.coli in 
Hmox1fl/fl versus LysM-Cre:Hmoxfl/fl mice (n=2-3 animals/group). Results shown as average ± SD, *P<0.05, *P<0.001. (D). 
Representative pictures of CD45 staining in mouse prostate as described in C, positive ells are indicated by arrows. (E-F) Quantification 
and representative pictures of p-HH3+ cells in wild type (Hmoxfl/fl) versus conditional HO-1 knock out mice (LysM-Cre:Hmoxfl/fl), treated 
as in C. Results shown as average ± SD, **P<0.01, *P<0.001. (E). Number of p-HH3+ cells per FOV in mice prostates as indicated in 
C. (F). Representative pictures of p-HH3 staining in mice described in D. Arrows indicate stained cells. 
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3.3. CO suppresses proliferation in the prostate  
In this study we investigated the potential of CO to regulate inflammation in the prostate. We applied CO at 250 
ppm for 1h, starting 1h after injection of bacteria i.u. Immunohistochemical staining with antibody against p-
HH3 indicated a decreased number of mitotic cells in the prostates from CO treated mice as compare to control 
mice at 3 weeks after injection of PBS or E.coli (Figure 3A-B). This effect correlated with lower activation of 
p-Erk1/2 in the prostate lysates of CO treated mice after injection of bacteria as visualized with western blot 
(Figure 3C). Staining of CD45 in prostate did not show any significant difference in numbers of infiltrating 
leukocytes between CO treated groups and Air controls after 3 weeks (Figure 3D-E). However, we noticed 
changes in levels of pro-IL-1β in the prostate lysates of Air versus CO treated animals analyzed by 
immunoblotting. Induction of pro-IL-1β was observed in prostates of CO treated individuals after 6h. After 24h, 
the pro-IL-1β had disappeared in the group of mice exposed to CO, while the Air treated animals showed 
induction of named pro-cytokine. The cleaved, active form of IL-1β did not seem to follow the changing 
concentrations of its precursor at the time-points tested. However, this might be due to detection problems of 
too low amounts of the target protein in the lysates. (Figure 3F). Intriguingly, these data show that CO in this 
context suppresses proliferation and tissue regeneration in the inflamed prostate. In addition, a faster induction 
and following suppression of the pro-inflammatory cytokine IL-1β precursor in response to CO treatment 
indicates an effect on immune cell phenotype and/or activation, possibly leading to more effective resolution. 
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3.4. Inflammation in the prostate induces lipid metabolic enzymes: Long chain acyl-CoA 
synthetase (ACSL1) and fatty acid synthase (FAS) – effect of CO and HO-1  
Lipid metabolic enzymes such as ACSL1 regulate immunological reactions. In our study we asked a question 
whether expression levels of lipid metabolic enzymes were affected by pathogen-induced prostatitis. 
Immunoblots showed induction of ACSL1 and FAS as early as 6h after injection, in comparison to naïve 
animals, with a stronger increase in E.coli exposed mice compared to PBS group (Figure 4A-B). Similar 
Figure 3: Impact of CO treatment on proliferation and inflammation in prostatitis. (A-C) IHC staining of phospho-histone H3 
(quantification and representative pictures) and immunoblot of phospho-Erk1/2, representing markers of division and proliferation, 
respectively, in prostates from air- versus CO treated WT mice inoculated with E.coli i.u. (2x108 CFU/animal), analyzed 24h and/or 3 
weeks after start of experiment. (A). Number of p-HH3+ cells in prostate from WT mice injected i.u. with PBS or E.coli (2x108 
CFU/animal. Mice treated with CO, starting 1h after infection (250 ppm for 1h) were compared to controls kept in air, 3 weeks after 
instillation of bacteria. Data shown as average ± SD, *P<0.05, ***P<0.001. (B). Representative pictures of p-HH3 staining presented in 
A. Arrows indicating cells stained with p-HH3 antibodies. (C). Immunoblot of p-Erk1/2 in mice 24h and 3 weeks after injection of PBS 
or E.coli ± CO treatment, as described in A. (D-F) Inflammation measured in mice by IHC (quantification and representative pictures of 
CD45+ cell infiltration in prostate) and immunoblotting of IL-1β, 6h, 24h and 3 weeks after E.coli injection and CO treatment as described 
in A, respectively. D. Quantification of CD45+ cells in prostate from mice treated as in A. Data shown as average ± SD. (E). 
Representative pictures or CD45+ cells shown in D. Arrows indicate cells positive for CD45 staining. (F). Immunoblot of pro-IL-1β 
(upper band-40 kDa) and cleaved IL-1β (lower band-17 kDa), TLR4 and cleaved Caspase 1 in air versus CO treated mice described 
as in A, analyzed 6h, 24h and 3 weeks, respectively after starting the experiment. 
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induction in expression of ASCL1 and FAS was observed after 24h and 3 weeks post-infection. FAS showed 
the strongest induction after 24h. Further, immunofluorescence staining of ACSL1 and CD45 (Figure 4C-D) 
showed that residential CD45+ leukocytes were positive for ACSL1 in normal prostate (Figure 4C). In inflamed 
tissue, ACSL1 was strongly induced in prostate epithelium 24h after injection of PBS and even more 
pronounced in the E.coli group (Figure 4D). The 3 week time-point yet needs to be evaluated.  
 
 
 
 
 
 
 
 
 
 
Further, we tested whether inhaled CO has any effect on the lipid metabolic enzymes and therefore we 
performed immunoblotting on prostate lysates from CO treated mice, as described earlier, and compared them 
to Air control mice (Figure 5A-B). Early induction of ACSL1, observed 2h after injection of E.coli, was almost 
totally abolished in CO treated mice as compared to controls (Figure 5A). Inhibition of ACSL1 was also seen 
in CO treated mice after 24h and 3 weeks (Figure 5B), even though it was not as strong as for the earliest time-
point tested. FAS was not changed in the early time point after application of CO, but was inhibited after 3 
weeks, both in PBS and E.coli treated mice. The 6h time-point is still under analysis. 
To evaluate the role of HO-1 in the model of prostatitis we analyzed the expression of ACSL1 and FAS in 
prostates from LysM-Cre:Hmox1fl/fl 24h after injection of bacteria or PBS (Figure 5C). We did not see any 
difference in ACSL1 protein levels between knock-out and wild type mice. FAS expression was strongly 
expressed in wild type PBS as compared to knock-out mice, while it was slightly lower in wild type as compared 
to LysM-Cre:Hmox1fl/fl in group of mice injected with E.coli. The 2h, 6h and 3 weeks-time points remain to be 
analyzed. 
 
 
Figure 4: Inflammation in the prostate is partly regulated by lipid metabolic enzymes ACSL1 and FAS. (A). Immunoblotting of 
FAS (Fatty Acid Synthase) and ACSL1 (Long Chain Acyl-CoA Synthetase) in prostate lysates from mice injected with PBS or E.coli 
(2x108 CFU/animal) and harvested 6h, 24h, and 3 weeks after injection, N=naïve control (B-C) Immunofluorescence (IF) co-staining of 
ACSL1 and CD45 in prostate from Naïve control and from PBS or E.coli injected animals after 6h and 24h, respectively. (B). IF co-
staining of ACSL1 (red) and CD45 (green), (nuclei stained blue) in normal (naïve) mouse prostate. (C). Co-staining as in B of prostate 
from mice harvested 6h and 24h after injection (i.u.) of PBS or E.coli (2x108 CFU/animal). 
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3.5. Anchorage independent growth of PC3 and PNT1A cells, respectively, is enhanced by 
E.coli induced macrophage derived factors, but can be suppressed in the former cell type by 
CO treatment. 
We wanted to investigate the potential of macrophage derived factors to promote anchorage independent 
growth, a characteristic of transformed and malignant cells, in the prostate cell lines PC3 (metastatic lesion of 
PCa) and PNT1A (transformed, but pre-malignant prostate cells). Preliminary results from quantifications of 
PC3 colonies cultured in soft agar showed that wells with cells treated with supernatant (for 18 days) from E.coli 
stimulated (10 MOI for 2h) WT BMDMs had significantly higher number of colonies compared to RPMI treated 
control (P<0.001) and supernatant from unstimulated BMDMs (P<0.05). However, the increase in PC3 colony 
number due to supernatant was suppressed when the BMDMs were treated with CO (250 ppm for 1h) starting 
1h after infection with E.coli P<0.001. Figure 6A-B). PNT1A cells grown as described above were generally 
more slow-growing and smaller in size than PC3 cells, but showed a similar pattern with increased number of 
colonies in the soft agar after 31 days of treatment with supernatant from E.coli activated BMDMs, compared 
to control P<0.001, and compared to sterile BMDMs P<0.05, but in contrast the increased potential of 
Figure 5: Inhaled CO suppresses induction of ACSL1 and FAS in the model pathogen-induced prostate inflammation. (A). 
Immunoblotting of ACSL1 (upper band) and FAS in prostate lysates from PBS- or E.coli injected WT mice (2x108 CFU/animal i.u.) ± 
CO (1h, 250 ppm starting 1h after injection, harvested directly after treatment. (B). Immunoblotting of ACSL1 and FAS in prostate 
lysates from WT mice treated as in A, harvested 24h and 3 weeks after treatment, Tub.=Tubing control (catheterized, but not injected). 
(C). Immunoblotting of ACSL1 and FAS in prostate lysates from mice with HO-1 deletion in myeloid cells (LysM-Cre:Hmox1fl/fl) versus 
wild type (Hmox1fl/fl) treated as in A, harvested 24h after injection. 
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anchorage-independent growth in the BMDM + E.coli supernatant treated group of PNT1A was not suppressed 
by CO treatment of the macrophages prior to harvest of supernatant (Figure 6C-D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Discussion 
Inflammation in the prostate is a common condition thought to be involved in the initiation and progression of 
BPH, PIN and prostate cancer. Bacterial urinary tract infections, in combination with urine reflux, cause chronic 
prostatitis due to repeated exposure of the tissues to irritants and pathogens. Abnormal proliferation of prostate 
cells in response to prostatitis is associated with increased concentration of growth factors in areas of 
inflammation (PIA), prostate gland size and lower urinary tract symptom severity (59, 60). Currently, there is a 
substantial lack of knowledge on the pathology and efficient curable treatment of chronic prostatitis. Today’s 
use of antibiotics, non-steroidal anti-inflammatory drugs along with analgesics and surgery that represent the 
Figure 6: Anchorage independent growth of PC3 and PNT1A cells, respectively in soft agar is enhanced by macrophage derived 
factors, but can be suppressed in the former cell type by CO treatment. (A-B) Quantification and representative pictures of PC3 cell 
colonies growing in soft agar after treatment with filtered supernatant from MCSF-differentiated Bone Marrow Derived Macrophages (BMDMs) 
treated with live E.coli (10 MOI for 2h) or 80 µl sterile PBS and exposed to CO (250 ppm for 1h) starting 1h after E.coli infection or left in 
standard conditions in air, thereafter media was changed and antibiotics added and supernatants were harvested 24h later (One experiment 
in triplicates). A. Number of PC3 colonies per field of view (FOV) in soft agar after 18 days of treatment with supernatant harvested from 
MCSF-differentiated BMDM ± E.coli (10 MOI for 2h) ± CO (250 ppm for 1h, starting 1h after E.coli infection) 24h after bacterial and CO 
treatments. Results shown as average ± SD. *P<0.05, **P<0.01, ***P<0.001. (B). Representative pictures of PC3 colonies treated as in A. 
(C-D) Quantification and representative pictures of PNT1A cell colonies in soft agar after 31 days of treatment M as indicted in A. *P<0.05, 
***P<0.001. (D). Representative pictures of PNT1A colonies described in C. RPMI: Negative control-growth media without BMDM contact. 
SP-: Supernatant from differentiated BMDM + 80 µl PBS. SP+: Supernatant from differentiated BMDMs + E.coli (10 MOI for 2h). Air: BMDMs 
kept in standard culture conditions 24h before harvest of supernatant. CO: BMDMs treated with CO (250 ppm for 1h) 24h prior to harvest of 
supernatants. 
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first-line treatment in the guide-line from the Prostatitis Expert Reference Group (PERG) primarily provide 
relief from pain and symptoms in patients with prostatitis, but often fail to cure the disease permanently (125). 
To target the immune system itself and redirect skewed immune responses might be a new strategy to help 
patients suffering from chronic prostatitis. This requires deeper understanding of the underlying mechanisms of 
the disease and also more attention in the literature.  
We investigated the role of myeloid-derived HO-1 and the effect of exogenously applied CO in pathogen-
induced non-lethal prostatitis. We established a mouse model of bacterial prostatitis by inoculating male mice 
(7-10 weeks old) with live E.coli MG1655 (2x108 CFU/animal) transurethrally. This method has been 
previously used with success (65, 67), causing evident prostatic inflammation with increased influx of 
inflammatory cells, proliferation of cells and finally transformation of prostate epithelium into pre-cancerous 
PIN lesions. Our results confirmed infiltration of CD45+ leukocytes, expression changes in cytokine (IL-1β, 
IL-10) and activation of MAPK signaling pathway, which is involved in proliferation. We also noted an 
increased cell division (p-HH3+ cells) in the prostates in animals injected with E.coli for 6h. Sustained 
inflammation was observed up to 3 weeks after injection, which indicates chronic prostatitis in these mice. 
Interestingly, mice injected with PBS also showed signs of inflammation after 24h, but the immune response 
was transient and was not significantly different from naïve controls after 3 weeks. This was earlier noted in 
mice by Kwon and colleagues (65), who explained the effect as a consequence of physical injury caused by the 
catheterization, urine reflux and increased pressure in the prostate due to injection of liquid. We noted that in 
order to minimize the risk of back-ground inflammation in the prostate all injections should be performed with 
great care and the solution should fulfill physiological conditions of the local environment in case of osmolarity 
and pH. Since PBS is sterile, yet induces urine reflux to the prostate upon the injection, it might represent a 
model of sterile prostatitis. 
Despite the transient activation of inflammatory responses by injection procedure, the transurethral injection 
does more adequately resemble the urinary tract infection pathology in humans than does the alternative method: 
direct intra-prostatic injection that is also used in prostatitis models in vivo. In addition, the intra-prostatic 
injection increases the risk of complications due to open surgery and also causes great tissue trauma and 
hemorrhage in the prostate after the procedure.  
HO-1 activity in macrophages has been documented to act differently on inflammatory processes depending on 
the cellular context, being able to trigger lytic function in immune cells but also promote immunosuppressive 
cells, such as T regulatory cells and inhibit antigen presenting cell maturation and function (126-129). In our 
study, we showed induction of HO-1 in the prostate after injection of PBS or E.coli and localization to the 
stroma, indicating activation of stromal cells in response to the tissue insult. Yet, this data is preliminary and 
needs to be confirmed by complementary analyses and further investigated in terms of different time points and 
additional animals. Technical issues regarding western blots and immunohistochemistry left the experiment to 
be completed after trouble-shooting of staining methods. Further, when applying the model in mice with HO-1 
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deficient myeloid cells we observed an increase in inflammatory infiltrates in these mice as compared to wild 
type controls indicating an impact of myeloid derived HO-1 on inflammatory responses in the prostate. 
However, further experiments are needed to explain the mechanism behind the role of HO-1 in this model. Early 
induction of IL-1β after infection and even higher levels in CO treated mice are in accordance with earlier results 
from our group (96), suggesting HO-1 and CO as a co-stimulatory signal for macrophage activation in response 
to bacteria. Our results indicate CO triggering an earlier burst of pro-IL-1β protein, shown after 6h in comparison 
to Air treated controls, where the cytokine is not induced until 24h after bacterial challenge.  An increased influx 
of immune cells in HO-1 knockout mice might indicate that HO-1 activity mediate the initial phase of bacterial 
clearance (95, 130), inhibiting development of acute prostatitis. The rate of proliferation was not associated with 
lack of myeloid derived HO-1. Proliferation and differentiation in the prostate are both regulated by steroid 
hormones via a complex paracrine signaling between stromal cells and epithelium (63, 131). Our studies suggest 
that expression of HO-1 might not regulate proliferation yet influence other changes in the cells that contribute 
to carcinogenesis. Additional studies how the heme degradation pathway may have effect on prostate cell 
proliferation are required to investigate the cross-talk between androgen signaling and metabolic pathways. 
Even though lack of myeloid derived HO-1 was not shown to affect the proliferation rate, inhalation of CO for 
1h after induction of prostatitis was able to suppress cell division in wild type mice injected with bacteria in the 
3 weeks’ time point. Earlier, CO has been shown to promote regeneration of injured tissues (89, 93), however 
these results originate from studies using inflammations induced by heme toxicity and trauma. HO-1 and CO 
work in a situation-dependent manner to favor host survival, potent of initiate different types of responses.  CO 
might act to restore homeostasis by suppressing proliferation and prevent development of hyperplasia and 
sequential PIN lesions. Indeed CO suppressed growth of prostate cancer and PIN development in TRAMP 
prostate cancer model in mice (111).  
 Fatty lipid metabolism enzymes ACSL1 and FAS have been shown to be liked to macrophage activation and 
inflammation in diabetic mice (123) as well as to prostate cancer (116). In normal, non-inflamed tissue we found 
that ACSL1 was almost exclusively expressed in CD45+ leukocytes, indicating a role of this enzyme in the 
function of residing tissue macrophages. We also observed strong induction of ACSL1 and FAS in the epithelial 
cells after bacterial challenge. These results indicate that FAS and ACSL1 are regulators of the inflammatory 
process in the prostate following bacterial infection. Interestingly, the induction of ACSL1 was rapidly inhibited 
by CO treatment, which indicates that CO might regulate the inflammation, at least in part, through the lipid 
metabolic enzyme ACSL1. We have not established whether CO works directly on the epithelium or only on 
macrophages, as indicated in a preliminary figure illustrating our hypothesis (Figure 7). CO mediated 
suppression of proliferation might be mediated in part through lipid metabolic enzymes. If CO inhibits activation 
and production of fatty acids which are utilized for diverse anabolic processes in the epithelial cells, it might 
regulate their division directly by re-directing their metabolism. We have previously shown that CO targets 
glucose metabolism in cancer cells and thus blocks their proliferation (111).  
Lisa Vikström, Master’s Thesis 60 credits  2015-09-03 
Lund University, 2014-2015 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deregulation of the macrophage polarization status is known to play a role in chronic inflammation and cancer. 
Reprogramming of tumor associated macrophages into cancer promoting phenotype by cancer cells has been 
described in numerous studies. Anchorage-independent growth is a characteristic of malignant cells and 
preliminary data from one experiment showed that transformed prostate epithelial cells (PNT1A) and prostate 
adenocarcinoma cells (PC3) tended to grow larger colonies in soft agar, after treatment with supernatant from 
BIDMCs treated with E.coli for 2h than from non-stimulated macrophages. This indicate that factors released 
from bacteria-induced M1 macrophages are able to accelerate the malignant phenotype of prostate epithelial 
cells in different stages of transformation. Similar effects were previously noted by Helm et al. in a model of 
pancreatic cancer, where pro-inflammatory macrophages potently induced epithelial-mesenchymal-transition 
in transformed cells (77). CO treatment of bacteria-stimulated BIDMCs suppressed the growth of PC3 colonies, 
but not PNT1A colonies treated with this supernatant, as compared to Air treated control group, further 
supporting the theory of CO mediated inhibition of prostate proliferation, which we observed in our in vivo 
model of pathogen-induced prostatitis. This result indicates that CO effect on macrophages only, is able to cause 
regression of prostate adenocarcinoma cells. However, this experiment has to be repeated with more extensive 
analysis of supernatant content, macrophage activation and of the cellular response in prostate cells to the 
treatment. 
Figure 7: Possible modulation of bacteria-induced inflammation in prostate by HO-1/CO through decreased leukocyte 
infiltration and regulation of lipid metabolic enzymes FAS and ACSL1 in macrophages and/or epithelium. Chronic inflammation 
in the prostate involves macrophages with skewed polarization state, which promotes tumor formation and progression by release of 
reactive oxygen species (ROS), cytokines (i.e. TNF, IL-6) and growth factors (i.e. FGFs, EGF, VEGF), leading to DNA-damage, 
leukocyte recruitment, stroma activation and remodeling, angiogenesis, proliferation and transformation. Our study suggest a role of 
myeloid derived HO-1 in modulating the inflammatory responses following bacterial infection by decreasing the influx of inflammatory 
cells, possibly by enhancing bacterial clearance via inflammasome activation and IL-1β release. HO-1 does not directly have any impact 
on proliferation in our model of bacterial prostatitis. HO-1/CO might operate in other processes inhibiting tumorigenesis, in part by 
regulation of lipid metabolic enzymes FAS and ACSL1, either in epithelial cells or in macrophages. ACSL1: long chain acyl-CoA 
synthetase, CO: carbon monoxide, EGF: epithelial growth factor, FAS: fatty acid synthase, FGF: fibroblast growth factor, HO-1: 
hemeoxygenase-1, TNF: tumor necrosis factor. 
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5. Conclusion 
In summary, our results suggest that HO-1 in myeloid cells might have a regulatory function in the established 
model of bacterial infection, by decreasing the number of leukocytes present in the prostate. Further studies 
warrant investigation on the role of HO-1 in specific cell types, signaling pathways, inflammatory factors and 
proliferative responses of epithelial cells in the inflamed prostate. We provide the first evidences that CO 
treatment might have beneficial effect on inhibiting inflammation in the prostate, yet further proof-of-concept 
studies are required to evaluate potential therapeutic effects of CO in prostatitis. 
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